FTSE MIB
34.657,35 +318,03 (+0,93%) Dow Jones
39.512,84 +125,08 (+0,32%) Nasdaq
16.340,87 -5,40 (-0,03%) Nikkei 225
38.229,11 +155,13 (+0,41%) Petrolio
78,20 -1,06 (-1,34%) Bitcoin EUR
56.573,05 -1.716,73 (-2,95%)
Clearside Biomedical, Inc. (CLSD)
Dopo ore:
| Chiusura precedente | 1,3500 |
| Aperto | 1,3000 |
| Denaro | 1,2200 x 100 |
| Lettera | 1,2900 x 100 |
| Min-Max giorno | 1,2100 - 1,3100 |
| Intervallo di 52 settimane | 0,6500 - 2,1200 |
| Volume | |
| Media Volume | 377.546 |
| Capitalizzazione | 93,414M |
| Beta (5 anni mensile) | 2,36 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,5300 |
| Prossima data utili | 09 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 5,50 |
GlobeNewswireClearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3 2024 - ALPHARETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that key data from the Phase 1/2a OASIS clinical trial wer
- GlobeNewswire
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
- Continued Progress in the Global Development and Commercialization of XIPERE® (known as ARCATUS® in China) - ALPHARETTA, Ga., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that Arctic Vision, Clearside’s partner, has successfully completed enrollment in its Phase 3 randomized, double-blind, placebo-controlled clinical tri
- GlobeNewswire
Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit
ALPHARETTA, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Charles A. Deignan, Chief Financial Officer, will participate in a panel discussion at the JonesTrading 2023 Healthcare Summit. The panel, entitled, All About Eyes: Paradigm Shifting Therapeutic Innovations in Ophthalmology will take place on October
